logo-loader

Medlab outlines business development objectives at open day

Published: 23:00 04 Dec 2018 EST

arrow going upwards
Shares in the company last traded at 39 cents

Medlab Clinical Ltd’s (ASX:MDC) director of commercial operations Paul Vilner has outlined its business development objectives at its open day held at the Sydney suburb of Alexandria.

It plans to commercialise each of its four strategic pillars.

READ: Medlab Clinical expanding cannabis-based medicines into Europe

Medlab has 30 nutraceutical products (pharmaceutical-grade and standardised nutrients) globally, with another 10 in development.

Most of these products are sold as a companion to a prescription product and are available in over 600 pharmacies across Australia.

Pharmaceutical product range

Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™, which contain formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.

NanaBis™ and NanaBidial™ available to Australian patients for compassionate use under the government Special Access Scheme (SAS).

Spreading awareness of ability to access

Medlab has a dedicated team of medical specialist liaisons to support healthcare practitioners with patient initiation, SAS-B applications and clinical trial recruitment.

The company is actively collaborating with national clinical groups (RACGP) and patient support organisations (Chronic Pain Australia).

To date, doctors and pharmacists are reporting encouraging results, in both efficacy and medication substitution.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

9 hours, 12 minutes ago